glp-1 shortage guidance New on the use of GLP-1-based drugs in people with type 1 diabetes (T1D), due to be published later this year, will address the safety and optimal use of these medications Navigating Access: The Future of
Description
Glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide, dulaglutide, and liraglutide are subcutaneous injections used for type 2 diabetes and weight management

95% CI, 0.86-0.94)

Your dose may need to go up as your body adjusts to treatment

doi: 10.1210/jc.2013-3607 50 HybyeCThornMBhmB

Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME

GLP-1 analogues are relatively large peptide molecules, making skin penetration particularly challenging